metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population 2
mHNSCC - L1 - PDL1 positive 4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population 4
mHNSCC - L2 - PDL1 negative 2
mHNSCC - L2 - PDL1 positive 1
hepatocell cancer (HCC) 1

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open